Literature DB >> 15993518

A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.

Clarisse Lorin1, Frédéric Delebecque, Valérie Labrousse, Lucie Da Silva, François Lemonnier, Michel Brahic, Frédéric Tangy.   

Abstract

Live attenuated measles vaccine (MV) could provide a safe and efficient pediatric vaccination vector to immunize children simultaneously against measles and human immunodeficiency virus type 1 (HIV-1). To evaluate the capacity of a vector derived from the certified Schwarz measles vaccine (MVSchw) to prime effective cytotoxic T cells (CTL) and broad neutralizing antibodies against HIV-1 conserved epitopes, we generated recombinant MVSchw viruses expressing HIV-1 antigens. We demonstrate that a recombinant MVSchw virus expressing an HIV-1-derived CTL polyepitope primes effective HLA-A0201-restricted CTLs against multiple conserved HIV-1 epitopes in mice susceptible to measles and humanized for the major histocompatibility complex (MHC) class-I molecule HLA-A0201. Additionally, we show that a recombinant MVSchw virus expressing an HIV-1(89.6) gp140 glycoprotein whose hyper variable V1, V2 and V3 loops were deleted (DeltaV1V2V3gp140), induces broadly neutralizing antibodies against HIV-1 primary isolates. These results show that the MVSchw pediatric vaccination vector induces efficient cellular and humoral HIV-specific immune responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15993518     DOI: 10.1016/j.vaccine.2005.04.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  CombiHIVvac vaccine which contains polyepitope B and T- cell immunogens of HIV-1.

Authors:  L I Karpenko; S I Bazhan; A M Eroshkin; L R Lebedev; R V Uzhachenko; N A Nekrasova; O A Plyasunova; P A Belavin; S V Seregin; N K Danilyuk; E D Danilenko; B N Zaitsev; V I Masicheva; A A Ilyichev; L S Sandakhchiev
Journal:  Dokl Biochem Biophys       Date:  2007 Mar-Apr       Impact factor: 0.788

3.  Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques.

Authors:  Margherita Rosati; Candido Alicea; Viraj Kulkarni; Konstantin Virnik; Max Hockenbury; Niranjan Y Sardesai; George N Pavlakis; Antonio Valentin; Ira Berkower; Barbara K Felber
Journal:  Vaccine       Date:  2015-03-21       Impact factor: 3.641

4.  Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice.

Authors:  G Grant Welstead; Caterina Iorio; Ryan Draker; Jane Bayani; Jeremy Squire; Sompong Vongpunsawad; Roberto Cattaneo; Christopher D Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

5.  Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Authors:  R Xu; F Nasar; S Megati; A Luckay; M Lee; S A Udem; J H Eldridge; M A Egan; E Emini; D K Clarke
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

6.  Lipid Nanoparticles with Accessible Nickel as a Vaccine Delivery System for Single and Multiple His-tagged HIV Antigens.

Authors:  Weili Yan; Anekant Jain; Ronan O'Carra; Jerold G Woodward; Wenxue Li; Guanhan Li; Avindra Nath; Russell J Mumper
Journal:  HIV AIDS (Auckl)       Date:  2009-07-01

7.  Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.

Authors:  Hoyin Mok; Xing Cheng; Qi Xu; James R Zengel; Bandita Parhy; Jackie Zhao; C Kathy Wang; Hong Jin
Journal:  Open Virol J       Date:  2012-02-16

Review 8.  Replicating and non-replicating viral vectors for vaccine development.

Authors:  Marjorie Robert-Guroff
Journal:  Curr Opin Biotechnol       Date:  2007-12-11       Impact factor: 9.740

9.  Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine.

Authors:  Richard Stebbings; Michèle Février; Bo Li; Clarisse Lorin; Marguerite Koutsoukos; Edward Mee; Nicola Rose; Joanna Hall; Mark Page; Neil Almond; Gerald Voss; Frédéric Tangy
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

10.  Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus.

Authors:  Samantha Brandler; Marianne Lucas-Hourani; Arnaud Moris; Marie-Pascale Frenkiel; Chantal Combredet; Michèle Février; Hugues Bedouelle; Olivier Schwartz; Philippe Desprès; Frédéric Tangy
Journal:  PLoS Negl Trop Dis       Date:  2007-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.